Eris Lifesciences Partners with Natco Pharma for Rights to Weight-Loss Medication Semaglutide

Eris Lifesciences Partners with Natco Pharma to Commercialize Semaglutide in India

Key Highlights:

• Eris Lifesciences has formed a partnership with Natco Pharma to commercialize semaglutide in India, ahead of the blockbuster weight-loss drug's patent expiry.
• The partnership comes after Natco Pharma received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) on 14 February to manufacture generic semaglutide for the Indian market.
• The product is expected to launch in March 2026 and will target type 2 diabetes management, aligning with unmet needs in India's expanding metabolic care landscape.

Partnership Details:

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

• The collaboration will leverage Eris Lifesciences' commercial presence in the diabetes segment and Natco Pharma's manufacturing and regulatory prowess in complex formulations.
• Eris Lifesciences has a strong presence in diabetology with a wide specialist reach, having signed a long-term deal with Biocon in 2024 to acquire its domestic branded formulations business, including its insulin products.

Market Analysis:

• The deal frenzy to commercialize semaglutide in India comes on the heels of fast-expanding demand for weight-loss drugs like semaglutide.
• GLP-1 drug sales have already crossed ₹1,000 crore in less than a year of launches, with innovator drugs Mounjaro, Wegovy, and Ozempic dominating the market.
• The entry of generic versions of semaglutide, priced cheaply, is expected to further expand the market.

Patent Expiry:

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year

• Novo Nordisk is set to lose patent exclusivity for semaglutide in India in March 2026, paving the way for generic versions of the drug to enter the market.